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An 18-month old boy presented with axillary suppurative lymphadenitis, which failed to respond to con-
servative management. His care was transferred to pediatric surgeons for further management. Resolution
of the abscess was not achieved despite two incision and drainage procedures. Cultures obtained from the
abscess grew Serratia Marcescens, and Staphylococcus aureus. A diagnosis of chronic granulomatous disease
(CGD) was made, subsequently identiﬁed to be x-linked. Review of a chest X-ray previously reported as
normal identiﬁed focal consolidation. This was investigated with CT and thought to represent previous
granuloma with current Staphylococcus infection. The boy was started on prophylactic septrin and itraco-
nizole, in addition to 2 months of treatment antibiotics. The abscess healed, and a repeat CT demonstrated
resolution of the cavitating lung lesion. A gastrostomy was inserted in preparation for a T cell-depleted
haploidentical bone marrow transplantation, which to date appears to have been curative. Chronic granu-
lomatous disease is a rare genetic primary immunodeﬁciency associated with high mortality if diagnosis is
delayed. The recent establishment of a UKCGD registry has identiﬁed a far higher prevalence thanpreviously
thought. Stem cell transplantation now offers a potentially curative treatment, with better outcomes in
younger children. It is therefore essential that pediatric surgeons are aware of this diagnosis, and that
appropriate investigations are institutedwhen an abscess fails to resolve, or has cultured unusual organisms.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
An 18 month-old boy was transferred from his local hospital for
further management of right axillary suppurative lymphadenitis.
One week prior to this, a lesion with a punctum on his right chest
wall had been noted. This had discharged spontaneously and
scabbed over. The axillary lymphadenitis had been treated with a
4-day course of intravenous benzyl penicillin and ﬂucloxacillinwith
no improvement. An ultrasound showed features of a thick walled
abscess. The child was systemically well, with a white cell and
neutrophil count within the normal range, but a raised c-reactive
protein at 26.
An incision and drainage was performed, during which a small
amount of pus was obtained and sent for microscopy and culture.
The boy was discharged home without antibiotics.
Over the next 3 days, the abscess was noted to re-accumulate,
and a new lesion developed on the left chest wall. A course of oralInc. This is an open access article uco-amoxiclav was commenced. The boy was reviewed by the pe-
diatric surgery teamwho noted the swelling had reduced, but frank
pus was draining from the wound. Cultures were obtained from the
new chest wall lesion and the original abscess cavity, and sent for
microbiology and virology. The swab from the abscess grew
Staphylococcus aureus, resistant to penicillin, but sensitive to ﬂu-
cloxacillin, which was then started. The swab from the new chest
wall lesion was negative for herpes and varicella.
Three days later, the boy was re-admitted as the axillary abscess
showed no evidence of resolution, with copious discharge of pus.
Intravenous ﬂucloxacillin was commenced, and further swabs were
sent to exclude atypical mycobacteria. The boy was reviewed by a
pediatric infectious disease specialist. There was no history of
recent travel, no contact with TB and no past medical history of
note e speciﬁcally no previous boils, abscesses or recurrent in-
fections. The rest of the family were ﬁt and well. On examination
there was no cervical, inguinal or left axillary lymphadenopathy,
and no hepatosplenomegaly. The impression was that these lesions
were secondary to a virulent Staphylococcus aureus infection, and
panton valentine leukocidin (PVL) testing was requested. A chest
X-ray was performed to exclude pulmonary lesions and underlyingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Right axillary abscess following 2nd incision and drainage.
Fig. 3. CT chest revealed cavitating lesion in left lower lobe thought to represent
previous granuloma and current Staphylococcus aureus infection.
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further incision and drainagewas performed and a 10-day course of
clindamycin (initially intravenous, then oral) was added to the
ﬂucloxacillin (Fig. 1).
The delayed culture result from the ﬁrst incision and drainage
revealed growth of Serratia marcescens. As the boy was well, his
clindamycin was stopped and he continued ﬂucloxacillin orally.
When the culture result from the second incision and drainage also
revealed growth of Serratia marcescens, oral ciproﬂoxacin wasFig. 2. Chest X-ray demonstrating left mid zone consolidation.added to ﬂucloxacillin. He was discharged home to complete a
14-day course of antibiotics.
At the ﬁrst dressing change 2 days post-discharge, there was
persistent offensive pus. As the cultures from the abscess had
grown Serratia marcescens and Staphylococcus aureus, concern was
raised regarding a possible diagnosis of chronic granulomatous
disease (CGD). On the advice of the pediatric infectious disease
specialist, bloods were sent for a nitroblue tetrazolium (NBT) assay,
lymphocyte subsets, immunoglobulins and vaccine response. The
NBT assay conﬁrmed a diagnosis of CGD.
A PICC line was inserted and he was started on intravenous
meropenem and prophylactic itraconazole. Liver and splenic ab-
scesses were excluded with an ultrasound. Review of the initial
chest X-ray raised concern regarding left mid zone focal consoli-
dation. CT chest revealed a cavitating focal area of consolidation
within the left lower lobe, with multiple focal areas of calciﬁcation
within the left hilum, mediastinum and left lung. A specialist
opinion was sought, and it was felt that the appearances were
suggestive of previous granuloma and current Staphylococcus
aureus infection, with no typical features of fungal lung infection
(Figs. 2 and 3). Aspergillus titres and T-spot were negative.
The CT chest was repeated following a 2-month course of anti-
biotics. The cavitating lesion had resolved completely, with
persistence of chronic calciﬁc changes. Intravenous meropenem
was stopped, prophylactic septrin commenced and prophylactic
itraconizole continued (Fig. 4).
The boywas conﬁrmed to have x-linked CGD. A gastrostomywas
inserted in preparation for a T cell-depleted haploidentical bone
marrow transplant. He has made a very good recovery and now has
essentially normal neutrophil function.2. Discussion
Chronic granulomatous disease (CGD) is a rare genetic primary
immunodeﬁciency, associated with a high mortality if diagnosis is
delayed. Prevalence varies worldwide from 1 case per million to 1
Fig. 4. Summary of treatment.
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may also be autosomal recessive. As a consequence, 80% of patients
are male. Affected individuals have impaired phagocytosis, result-
ing from an inherited defect in one of the major subunits of the
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
complex. This complex catalyzes superoxide production, within the
phagocytic vacuole, generating reactive oxygen species, which
combinedwith the activity of myeloperoxidase, promotesmicrobial
death. Phagocytes in affected individuals are therefore able to
ingest, but not kill bacteria. Patients with chronic granulomatous
disease suffer from recurrent, frequently life-threatening bacterial
and fungal infections, particularly Staphylococcus aureus and
Aspergillus.
The name of the disease is derived from affected patients’ pre-
disposition to the formation of diffuse granuloma in hollow viscera.
Granuloma formation is thought to be the result of inﬂammation
secondary to dysregulated T-cell activity [3]. Affected patients may
present with obstructive symptoms or pain related to granuloma
formation in the esophagus, stomach, ureters and bladder, and
disorders secondary to extensive ﬁbrosis of the pulmonary,
gastrointestinal, genitourinary and central nervous systems [4e6].
In 2000, a United Kingdom and Ireland Chronic Granulomatous
Disease Registry was established and identiﬁed amuch higher birth
prevalence than previously thought e twice that reported in the US
and Japan, and four times that of Sweden [1,7e9]. Birth prevalence
between 1990 and 1999 was 7.5 per million, with a median age at
diagnosis of 2.7 years [7]. Consistent with the ﬁndings of other
groups, the age of diagnosis in male patients, and those withx-linked diseasewas signiﬁcantly lower [7,8,10]. Themedian age for
diagnosis in males and females was 2.5 years and 15.3 years
respectively, and 2.1 years in patients identiﬁed to have x-linked
recessive disease, compared to 17.8 years in patients with auto-
somal recessive disease [7]. The UK group identiﬁed suppurative
adenitis to be the most common presentation leading to diagnosis
of CGD, followed by abscesses and pneumonia [7].
The largest cohort described to date, which included 429 Euro-
pean patients (excluding UK), found the most prevalent site of
infection in patients with CGD to be lung, followed by skin, lymph
nodes, gastro-intestinal tract and liver [10]. There is relative con-
sistency in the literature regarding the most commonly isolated
organisms. The most commonly isolated organism in pneumonia is
Aspergillus species [7,8,10,11], and Staphylococcus aureus in skin
abscesses [8,10], suppurative adenitis [7,8,10] and liver abscesses
[7,8,10,11]. Osteomyelitis is most commonly associated with
Aspergillus species and Serratia marcescens [8,10].
Diagnosis is conﬁrmed using a nitroblue tetrazolium (NBT) assay
to demonstrate abnormal granulocyte oxidative burst. Nitroblue
tetrazolium dye is added to leukocyte-rich plasma, and the plasma
stimulated with the addition of yeast. Normally 85e95% of stimu-
lated neutrophils should demonstrate reduction of nitroblue
tetrazolium to blue-black formazan. If this is demonstrated by less
than 30% stimulated neutrophils, the test is suggestive of a diag-
nosis of chronic granulomatous disease. Following an abnormal
NBT test, genetic mutation analysis is usually performed to conﬁrm
the diagnosis.
The mainstay of treatment in the UK is antimicrobial and anti-
fungal prophylaxis, usually with sulfamethoxazole-trimethoprim
(Septrin) and itraconazole. Early recognition and aggressive treat-
ment of acute infections is imperative [12]. Courses of antimicrobial
therapy ranging fromweeks to months, sometimes in combination
with oral steroids [13e17], is often required. Steroids also have a
role in managing inﬂammatory complications, though steroid-
sparing treatments such as azathioprine and sulfasalazine may be
considered [4].
A controversial additional prophylactic treatment, used pri-
marily in the United States, is immunomodulation with interferon-
gamma (IFN). IFN has been shown to reduce the total number of
serious infections, regardless of age, prophylactic antibiotic use and
mode of inheritance [18]. Children under the age of 10 were shown
to beneﬁt the most from this therapy, and experienced the fewest
side effects. Concern over its use centers mostly around cost and the
need for regular subcutaneous injections. However, in combination
with antimicrobial prophylaxis, the relative risk of severe infection
can be reduced by as much as 67% [18e20]. IFN therapy is
commonly used for prophylaxis in the United States, whereas in
Europe it is limited to the occasional use for management of
particularly resistant infections or complications.
The recent gold standard of care, which is potentially curative, is
hematopoietic cell transplantation (HCT). The best outcomes are
achieved in younger patients [21], especially prior to secondary end
organ damage resulting from recurrent infection. However, HCT is
replete with risks including graft-versus host disease, over-
whelming infection, and rejection, with a 10% risk of mortality [22].
Overall mortality has been recently identiﬁed by the UK registry
as 27% at 20 years, with no difference between sexes [10]. The most
common cause of death is pneumonia, particularly if associated
with Aspergillosis, followed by septicemia [7,10].
3. Conclusion
Chronic granulomatous disease is a severe life-threatening pri-
mary immunodeﬁciency, that commonly presents with suppurative
adenitis and skin abscesses. Pediatric surgeons therefore need to be
C. Pardy et al. / J Ped Surg Case Reports 9 (2016) 5e88aware of the disorder, and consider appropriate investigation when
managing a persistent abscess or an abscess from which unusual
organisms are identiﬁed. The child described in this report has been
diagnosed at a young age, and has undergone potentially curative
stem cell transplantation.References
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